May 9, 2025, 20:58

Damon Runyon Quantitative Biology Fellowship Award

The Damon Runyon Cancer Research Foundation is now accepting applications for the 2026 Quantitative Biology Fellowship Award, a unique opportunity for exceptional postdoctoral scientists working at the intersection of cancer biology and computational science.

This highly competitive award funds researchers who are tackling computational challenges in cancer using innovative interdisciplinary approaches in both wet lab and dry lab settings.

Who is eligible?

Applicants must:

Hold a PhD, MD/PhD, or equivalent, with degree conferred between Dec 2, 2020 – Dec 2, 2025
Have joined their Mentors’ labs on or after Dec 2, 2023
Be within 24 months of joining both Mentors’ labs
Have two Mentors: one computational (dry lab) and one experimental (wet lab)
Apply via ProposalCentral by December 2, 2025 (4:00 PM ET)

Award details:

Three-year fellowship totaling $240,000
Focused on advancing quantitative biology in cancer research
Research must address a significant computational challenge in the field
Preference given to mentorship teams in close physical proximity

Required materials include:

Research proposal (5 pages max) and summary
Statement on computational innovation and methodological challenges (250 words each)
NIH-format biosketches for applicant and both mentors
Joint training plan and mentorship history
Three reference letters (including thesis advisor if applicable)
Applicant letter, personal statement, and long-term career commitment
Collaboration letters (optional)

Key dates:

Deadline: December 2, 2025 (4:00 PM ET)
Selection Meeting: February 27, 2026
Award Start Date: April–June 2026

Contact:

Email: [email protected]

More info: www.damonrunyon.org

AI in cancer bioinformatics cancer data science Cancer research computational biology Damon Runyon Early-career researchers interdisciplinary science OncoDaily Postdoctoral Fellowship proposalCENTRAL Quantitative Biology Fellowship wet lab dry lab

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research